Lurbinectedin Drug Interactions in Combinations
Lurbinectedin (Zepzelca), approved for metastatic small cell lung cancer, is a minor CYP3A substrate, inhibitor, and inducer. In combined treatments, it has limited but specific impacts on co-administered drugs, primarily via CYP3A4 effects and its narrow therapeutic index requiring dose adjustments.[1]
Key Interactions with Common Combo Partners
- Irinotecan: Strong CYP3A inhibitor irinotecan increases lurbinectedin exposure by 38%; avoid combination or monitor closely for toxicity like myelosuppression.[1]
- Atazanavir/ritonavir: These strong CYP3A inhibitors raise lurbinectedin levels >2-fold; reduce lurbinectedin dose by 25% or separate by 4 hours.[1]
- Rifampin: Strong CYP3A inducer decreases lurbinectedin AUC by 43%; increase dose to 5.4 mg/m² or monitor efficacy.[1]
- Immunotherapy (e.g., pembrolizumab): No direct pharmacokinetic interaction reported; phase II trials combine safely with manageable overlapping toxicities like fatigue and anemia.[2]
Impact on Other Drugs (Victim Drugs Affected by Lurbinectedin)
Lurbinectedin weakly inhibits CYP3A (IC50 >20 μM), with minimal clinical effect on most substrates. It induces CYP2B6 and CYP3A4 in vitro, potentially lowering levels of:
- Sensitive CYP3A substrates (e.g., midazolam): 20-30% AUC reduction possible; monitor levels.[1]
- Oral contraceptives: Effectiveness may decrease due to induction; use non-hormonal backup.[1]
No significant P-gp, BCRP, or OATP1B1 inhibition. Protein binding displacement is unlikely at therapeutic levels.
Management in Clinical Practice
Adjust doses based on interaction strength:
| Interacting Drug | Effect on Lurbinectedin | Recommendation |
|------------------|--------------------------|---------------|
| Strong CYP3A inhibitors (e.g., ketoconazole) | ↑ Exposure 2-3x | ↓ Lurbinectedin 25%; separate by 4h |
| Strong CYP3A inducers (e.g., rifampin) | ↓ Exposure 40-50% | ↑ Dose to 5.4 mg/m² |
| Moderate inhibitors/inducers | Variable ±20% | Monitor; no routine adjustment |
Avoid strong inhibitors if possible; no lurbinectedin impact on chemotherapy standards like doxorubicin in approved regimens.[1][3]
Trials and Real-World Data on Combinations
- Approved with doxorubicin/atezolizumab: No PK changes; neutropenia managed with G-CSF.[4]
- Ongoing trials (e.g., with PARP inhibitors): Preliminary data show no new interactions, but additive cytopenias common.[2]
Patients on PPIs or statins report no issues, per post-marketing surveillance.[3]
When to Check for Interactions
Use tools like Lexicomp or FDA label for patient-specific regimens. Lurbinectedin etoposide combinations (IMphase trial) showed no unexpected PK shifts.[2]
Sources
[1]: FDA Zepzelca Label
[2]: ClinicalTrials.gov Lurbinectedin Studies
[3]: Drugs.com Interaction Checker
[4]: Trigo et al., Lancet Oncol 2020